NFKB1 and colitis: Based on these findings, the use of the antimalarial drug artesunate was evaluated, and the results showed that it suppressed NF-κB signaling by suppressing miR-155 in a TNBS-induced colitis model and in LPS-induced RAW 264.7 mouse macrophages, promoting its potential use as a therapeutic strategy in UC patients [74].